A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan

A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon [PF-01913539] On The Single-Dose Pharmacokinetics Of The CYP2D6 Substrate Dextromethorphan In Healthy Subjects

This drug-drug interaction study is being conducted to evaluate the potential effect of Dimebon on the pharmacokinetics on dextromethorphan, a probe substrate of the cytochrome P450 2D6 (CYP2D6) enzyme, after multiple dose administration to healthy adult subjects.

Inclusion Criteria:

• Healthy adult subjects.
• Extensive or ultra-rapid metabolizers of CYP2D6 substrates, predicted by genotype.

Exclusion Criteria:

• Existence of significant medical conditions that would impact study results or pose unacceptable risks to study subjects.
• Pregnant or nursing females or females of childbearing potential who are unwilling or unable to use an acceptable method of contraception.
• Use of prescription or nonprescription drugs and dietary supplements within 7 days prior to the first dose of study medication.